223 related articles for article (PubMed ID: 26312729)
1. Vemurafenib and cutaneous adverse events--report of five cases.
Silva Gde B; Mendes AP; de Macedo MP; Pinto CA; Gibbons IL; Duprat Neto JP
An Bras Dermatol; 2015; 90(3 Suppl 1):242-6. PubMed ID: 26312729
[TBL] [Abstract][Full Text] [Related]
2. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
Keating GM; Lyseng-Williamson KA
Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082
[TBL] [Abstract][Full Text] [Related]
3. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
Owen JL; Lopez IE; Desai SR
J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
[TBL] [Abstract][Full Text] [Related]
5. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.
Carlos G; Anforth R; Clements A; Menzies AM; Carlino MS; Chou S; Fernandez-Peñas P
JAMA Dermatol; 2015 Oct; 151(10):1103-9. PubMed ID: 26200476
[TBL] [Abstract][Full Text] [Related]
7. Vemurafenib: in unresectable or metastatic melanoma.
Keating GM
BioDrugs; 2012 Oct; 26(5):325-34. PubMed ID: 22946753
[TBL] [Abstract][Full Text] [Related]
8. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma.
Dika E; Patrizi A; Ribero S; Fanti PA; Starace M; Melotti B; Sperandi F; Piraccini BM
Eur J Dermatol; 2016 Jun; 26(3):232-9. PubMed ID: 27019511
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
Vanneste L; Wolter P; Van den Oord JJ; Stas M; Garmyn M
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317
[TBL] [Abstract][Full Text] [Related]
10. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
11. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients.
Boussemart L; Routier E; Mateus C; Opletalova K; Sebille G; Kamsu-Kom N; Thomas M; Vagner S; Favre M; Tomasic G; Wechsler J; Lacroix L; Robert C
Ann Oncol; 2013 Jun; 24(6):1691-7. PubMed ID: 23406731
[TBL] [Abstract][Full Text] [Related]
12. A case of vemurafenib-induced polyarhritis in a patient with melanoma: how to manage it?
Babacan T; Türkbeyler IH; Balakan O; Pehlivan Y; Suner A; Kısacık B
Int J Rheum Dis; 2017 Mar; 20(3):398-401. PubMed ID: 24815010
[TBL] [Abstract][Full Text] [Related]
13. Vemurafenib in the French temporary authorization for use metastatic melanoma cohort: a single-centre trial.
Fennira F; Pagès C; Schneider P; Sidina I; Viguier M; Basset-Seguin N; Madjlessi-Ezra N; Madelaine I; Bagot M; Battistella M; Porcher R; Mourah S; Lebbé C
Melanoma Res; 2014 Feb; 24(1):75-82. PubMed ID: 24241686
[TBL] [Abstract][Full Text] [Related]
14. Abrupt development of Dupuytren's contractures with the BRAF inhibitor vemurafenib.
Sibaud V; Chevreau C
Joint Bone Spine; 2014 Jul; 81(4):373-4. PubMed ID: 24468667
[No Abstract] [Full Text] [Related]
15. Cutaneous Eyelid Neoplasms as a Toxicity of Vemurafenib Therapy.
Yin VT; Wiraszka TA; Tetzlaff M; Curry JL; Esmaeli B
Ophthalmic Plast Reconstr Surg; 2015; 31(4):e112-5. PubMed ID: 24833447
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.
Sinha R; Larkin J; Gore M; Fearfield L
Br J Dermatol; 2015 Oct; 173(4):1024-31. PubMed ID: 26109403
[TBL] [Abstract][Full Text] [Related]
17. Improved overall survival in melanoma with combined dabrafenib and trametinib.
Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
[TBL] [Abstract][Full Text] [Related]
18. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
Seeley AR; De Los Santos JF; Conry RM
Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037
[TBL] [Abstract][Full Text] [Related]
19. Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma.
Guerreschi P; Scalbert C; Qassemyar A; Kluza J; Ravasi L; Huglo D; Martinot-Duquennoy V; Formstecher P; Marchetti P; Mortier L
Melanoma Res; 2013 Oct; 23(5):373-80. PubMed ID: 23852164
[TBL] [Abstract][Full Text] [Related]
20. Vemurafenib. Value unclear in metastatic melanoma.
Prescrire Int; 2012 Dec; 21(133):288-90. PubMed ID: 23373092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]